Table 2.

Overview of summary evaluation metrics

Metric	Description
Dose intensity	Fraction of the dose compared to the maximum unreduced dose.
Neutropenia	Incidence and duration of grade 3 and 4 neutropenia.
Efficacy: survival	Median individual predicted overall survival based on PSA disease progression model and other covariates.
Life-years gained (LYG)	Median individual differences in overall survival between two competing treatments
Total treatment costs
Incremental cost-effectiveness ratio (ICER)
Quality-of-life (QOL)
Quality-adjusted life years (QALY)

i = individual i.